LU92307I9 - - Google Patents
Info
- Publication number
- LU92307I9 LU92307I9 LU92307C LU92307C LU92307I9 LU 92307 I9 LU92307 I9 LU 92307I9 LU 92307 C LU92307 C LU 92307C LU 92307 C LU92307 C LU 92307C LU 92307 I9 LU92307 I9 LU 92307I9
- Authority
- LU
- Luxembourg
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002336843 | 2002-11-20 | ||
| JP2003065807 | 2003-03-11 | ||
| JP2003139616 | 2003-05-16 | ||
| PCT/JP2003/014773 WO2004046115A1 (ja) | 2002-11-20 | 2003-11-20 | ４−オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LU92307I2 LU92307I2 (fr) | 2014-01-13 |
| LU92307I9 true LU92307I9 (enExample) | 2019-01-17 |
Family
ID=32329647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU92307C LU92307I2 (fr) | 2002-11-20 | 2013-11-11 | Elviégravir sous toutes ses formes comme protégéespar le brevet de base |
Country Status (31)
| Country | Link |
|---|---|
| US (6) | US7176220B2 (enExample) |
| EP (5) | EP2161258A3 (enExample) |
| KR (1) | KR100665919B1 (enExample) |
| AR (2) | AR042095A1 (enExample) |
| AT (1) | ATE443048T1 (enExample) |
| AU (1) | AU2003302029B8 (enExample) |
| BE (1) | BE2013C063I2 (enExample) |
| BR (1) | BRPI0306214B1 (enExample) |
| CA (1) | CA2470365C (enExample) |
| CY (2) | CY1110690T1 (enExample) |
| CZ (1) | CZ2004764A3 (enExample) |
| DE (1) | DE60329318D1 (enExample) |
| DK (1) | DK1564210T5 (enExample) |
| ES (1) | ES2329240T3 (enExample) |
| FR (1) | FR13C0061I2 (enExample) |
| HU (1) | HUS1300066I1 (enExample) |
| IL (2) | IL162548A0 (enExample) |
| LT (1) | LTPA2013018I1 (enExample) |
| LU (1) | LU92307I2 (enExample) |
| MX (1) | MXPA04006553A (enExample) |
| MY (1) | MY136173A (enExample) |
| NO (3) | NO327098B1 (enExample) |
| NZ (1) | NZ533641A (enExample) |
| PE (1) | PE20040840A1 (enExample) |
| PT (1) | PT1564210E (enExample) |
| SI (1) | SI1564210T1 (enExample) |
| SK (1) | SK2662004A3 (enExample) |
| TR (1) | TR200401663T1 (enExample) |
| TW (1) | TWI248928B (enExample) |
| WO (1) | WO2004046115A1 (enExample) |
| ZA (1) | ZA200404537B (enExample) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7169780B2 (en) | 2001-10-26 | 2007-01-30 | Istitute Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
| DE60329318D1 (de) * | 2002-11-20 | 2009-10-29 | Japan Tobacco Inc | 4-oxochinolinverbindungen und deren verwendung als hiv-integrase-inhibitoren |
| EP1730135B1 (en) | 2004-03-10 | 2010-09-22 | The United States of America, represented by the Secretary, Department of Health and Human Services | Qiunolin-4-ones as inhibitors of retroviral integrase for the treatment of hiv, aids and aids related complex (arc) |
| MY134672A (en) * | 2004-05-20 | 2007-12-31 | Japan Tobacco Inc | Stable crystal of 4-oxoquinoline compound |
| WO2005113509A1 (en) * | 2004-05-20 | 2005-12-01 | Japan Tobacco Inc. | Novel 4-oxoquinoline compound and use thereof as hiv integrase inhibitor |
| US8633219B2 (en) * | 2004-05-21 | 2014-01-21 | Japan Tobacco Inc. | Combination therapy |
| WO2006033422A1 (ja) * | 2004-09-21 | 2006-03-30 | Japan Tobacco Inc. | キノリジノン化合物、およびそのｈｉｖインテグラーゼ阻害剤としての利用 |
| US7745459B2 (en) * | 2004-09-21 | 2010-06-29 | Japan Tobacco Inc. | Quinolizinone compound and use thereof as HIV integrase inhibitor |
| UA87884C2 (uk) * | 2004-12-03 | 2009-08-25 | Мерк Энд Ко., Инк. | Безводна кристалічна калієва сіль інгібітора віл-інтегрази |
| US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
| US20070032522A1 (en) * | 2005-07-01 | 2007-02-08 | Kumar Dange V | Antiviral agents |
| WO2007063869A1 (ja) * | 2005-11-30 | 2007-06-07 | Japan Tobacco Inc. | 高純度キノロン化合物の製造方法 |
| US20090233964A1 (en) * | 2005-12-30 | 2009-09-17 | Gilead Sciences, Inc. | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
| AU2013203476C1 (en) * | 2005-12-30 | 2016-11-17 | Gilead Sciences, Inc. | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
| JP4676536B2 (ja) * | 2005-12-30 | 2011-04-27 | ギリアド サイエンシズ， インコーポレイテッド | Ｈｉｖインテグラーゼ阻害剤の薬物動態の改善方法 |
| EP2452682A1 (en) | 2006-02-01 | 2012-05-16 | Japan Tobacco, Inc. | Use of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or salt thereof for treating retrovirus infection |
| WO2007092802A1 (en) * | 2006-02-09 | 2007-08-16 | Boehringer Ingelheim International Gmbh | Method for treating hiv infection through co-administration of tipranavir and gs 9137 |
| KR101023635B1 (ko) | 2006-03-06 | 2011-03-22 | 니뽄 다바코 산교 가부시키가이샤 | 4-옥소퀴놀린 화합물 제조 방법 |
| CN101437801B (zh) * | 2006-03-06 | 2013-02-06 | 日本烟草产业株式会社 | 制备4-氧代喹啉化合物的方法 |
| PE20080697A1 (es) | 2006-05-03 | 2008-08-05 | Boehringer Ingelheim Int | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion |
| RU2399616C1 (ru) * | 2006-06-23 | 2010-09-20 | Джапан Тобакко Инк. | Производное 6-(гетероциклзамещенный бензил)-4-оксохинолина и его применение в качестве ингибитора интегразы вич |
| TW200811153A (en) | 2006-06-23 | 2008-03-01 | Japan Tobacco Inc | 6-(heterocyclyl-substituted benzyl)-4-oxoquinoline compound and use thereof as HIV integrase inhibitor |
| PL2049506T5 (pl) | 2006-07-07 | 2024-09-09 | Gilead Sciences, Inc. | Modulatory farmakokinetycznych właściwości leków |
| WO2008010953A2 (en) | 2006-07-19 | 2008-01-24 | University Of Georgia Research Foundation, Inc. | Pyridinone diketo acids: inhibitors of hiv replication in combination therapy |
| EP2644587A3 (en) * | 2006-09-12 | 2013-10-23 | Gilead Sciences, Inc. | Process and intermediates for preparing integrase inhibitors |
| NZ575831A (en) | 2006-09-29 | 2011-12-22 | Idenix Pharmaceuticals Inc | Enantiomerically pure phosphoindoles as hiv inhibitors |
| KR20100049698A (ko) | 2006-12-22 | 2010-05-12 | 아벡사 리미티드 | 바이사이클 피리미디논 및 그 용도 |
| EP3150586B1 (en) | 2007-02-23 | 2020-01-08 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
| NZ582086A (en) * | 2007-06-29 | 2012-07-27 | Gilead Sciences Inc | Therapeutic compositions and the use thereof |
| AP2490A (en) * | 2007-06-29 | 2012-10-04 | Gilead Sciences Inc | Therapeutic compositions and the use thereof |
| PE20090938A1 (es) | 2007-08-16 | 2009-08-08 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo |
| AR068403A1 (es) * | 2007-09-11 | 2009-11-18 | Gilead Sciences Inc | Proceso e intermediarios para la preparacion de inhibidores de integrasa |
| EP2197847B1 (en) * | 2007-09-12 | 2012-11-07 | Concert Pharmaceuticals Inc. | Deuterated 4 -oxoquinoline derivative for the treatment of hiv infection |
| US8377960B2 (en) * | 2007-11-15 | 2013-02-19 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
| NZ585226A (en) | 2007-11-16 | 2012-08-31 | Gilead Sciences Inc | Inhibitors of human immunodeficiency virus replication |
| EP2234608A2 (en) | 2007-12-11 | 2010-10-06 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties |
| WO2009089263A2 (en) * | 2008-01-07 | 2009-07-16 | Ardea Biosciences Inc. | Novel compositions and methods of use |
| EP2296633B1 (en) | 2008-05-02 | 2015-09-30 | Gilead Sciences, Inc. | The use of solid carrier particles to improve the processability of a pharmaceutical agent |
| WO2010073078A2 (en) * | 2008-12-22 | 2010-07-01 | Orchid Research Laboratories Ltd. | Heterocyclic compounds as hdac inhibitors |
| NZ594214A (en) * | 2009-02-06 | 2013-05-31 | Gilead Sciences Inc | Tablets comprising cobicistat, elvitegravir, emtricitabine and tenofovir disoproxil fumarate for combination therapy |
| SG173619A1 (en) | 2009-02-13 | 2011-09-29 | Boehringer Ingelheim Int | Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof |
| WO2010137032A2 (en) * | 2009-05-14 | 2010-12-02 | Matrix Laboratories Ltd. | Novel polymorphic forms of elvitegravir and its pharmaceutically acceptable salts |
| WO2011004389A2 (en) | 2009-06-18 | 2011-01-13 | Matrix Laboratories Ltd | An improved process for the preparation of elvitegravir |
| WO2011025683A1 (en) * | 2009-08-26 | 2011-03-03 | Merck Sharp & Dohme Corp. | Hiv integrase inhibitors |
| MX2012002942A (es) | 2009-09-30 | 2012-04-11 | Boehringer Ingelheim Int | Metodo para la preparacion de una forma cristalina de 1-cloro-4-(beta-d-glucopiranos-1-il)-2-(4-((s)-teteahidrofuran-3- iloxi)bencil)-benceno. |
| CN102574829B (zh) | 2009-09-30 | 2015-07-01 | 贝林格尔.英格海姆国际有限公司 | 吡喃葡萄糖基取代的苄基-苯衍生物的制备方法 |
| US10610489B2 (en) | 2009-10-02 | 2020-04-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
| CA2777664C (en) | 2009-10-13 | 2014-06-10 | Johannes Wilhelmus J. Thuring | Macrocyclic integrase inhibitors |
| MY172005A (en) | 2009-12-07 | 2019-11-11 | Univ Georgia | Pyridinone hydroxycyclopentyl carboxamides : hiv integrase inhibators with therapeutic applications |
| CN102958935B (zh) | 2010-04-02 | 2015-12-09 | 爱尔兰詹森科学公司 | 大环整合酶抑制剂 |
| DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
| US9102614B2 (en) | 2010-07-02 | 2015-08-11 | Gilead Sciences, Inc. | Naphth-2-ylacetic acid derivatives to treat AIDS |
| WO2012003498A1 (en) | 2010-07-02 | 2012-01-05 | Gilead Sciences, Inc. | 2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds |
| AR085689A1 (es) | 2011-03-07 | 2013-10-23 | Boehringer Ingelheim Int | Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2 |
| PE20141066A1 (es) | 2011-04-21 | 2014-09-05 | Gilead Sciences Inc | Compuestos de benzotiazol |
| US9376392B2 (en) | 2012-01-04 | 2016-06-28 | Gilead Sciences, Inc. | 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS |
| WO2013103738A1 (en) | 2012-01-04 | 2013-07-11 | Gilead Sciences, Inc. | Napthalene acetic acid derivatives against hiv infection |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| US9192617B2 (en) | 2012-03-20 | 2015-11-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| PH12014500842A1 (en) | 2012-04-20 | 2014-06-09 | Gilead Sciences Inc | Benzothiazol-6-yl acetic acid derivatives and their use for treating an hiv infection |
| CA2878699C (en) | 2012-08-03 | 2018-09-11 | Gilead Sciences, Inc. | Process and intermediates for preparing integrase inhibitors |
| CZ304983B6 (cs) | 2012-10-12 | 2015-03-11 | Zentiva, K.S. | Způsob výroby a nové intermediáty syntézy elvitegraviru |
| CZ304984B6 (cs) | 2012-10-12 | 2015-03-11 | Zentiva, K.S. | Zlepšený způsob výroby a nové intermediáty syntézy elvitegraviru |
| NZ709260A (en) | 2012-12-21 | 2016-07-29 | Gilead Sciences Inc | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
| PL2938185T3 (pl) | 2012-12-26 | 2020-11-02 | Société des Produits Nestlé S.A. | Kompozycje powlekanego żwirku dla zwierząt o niskiej gęstości |
| HUE041709T2 (hu) | 2013-04-05 | 2019-05-28 | Boehringer Ingelheim Int | Az empagliflozin terápiás alkalmazásai |
| US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| CA2812519A1 (en) | 2013-04-05 | 2014-10-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| HK1213818A1 (zh) | 2013-04-05 | 2016-07-15 | 勃林格殷格翰国际有限公司 | 依帕列净的治疗用途 |
| PT2986304T (pt) | 2013-04-18 | 2022-02-25 | Boehringer Ingelheim Int | Composição farmacêutica, métodos para o tratamento e suas utilizações |
| CZ307255B6 (cs) * | 2013-07-11 | 2018-05-02 | Zentiva, K.S. | Nový způsob přípravy elvitegraviru |
| ES2859102T3 (es) | 2013-07-12 | 2021-10-01 | Gilead Sciences Inc | Compuestos de carbamoilpiridona policíclica y su uso para el tratamiento de infecciones por VIH |
| NO2865735T3 (enExample) | 2013-07-12 | 2018-07-21 | ||
| NO2717902T3 (enExample) | 2014-06-20 | 2018-06-23 | ||
| TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
| TWI677489B (zh) | 2014-06-20 | 2019-11-21 | 美商基利科學股份有限公司 | 多環型胺甲醯基吡啶酮化合物之合成 |
| WO2016081464A1 (en) | 2014-11-17 | 2016-05-26 | Nirogyone Therapeutics, Inc. | Monocarboxylate transport modulators and uses thereof |
| TWI695003B (zh) | 2014-12-23 | 2020-06-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
| SI3466490T1 (sl) | 2015-04-02 | 2020-12-31 | Gilead Sciences, Inc. | Policiklične spojine karbamoilpiridona in njihova farmacevtska uporaba |
| WO2016193997A2 (en) * | 2015-06-03 | 2016-12-08 | Msn Laboratories Private Limited | Process for the preparation of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid and pharmaceutically acceptable salts thereof |
| MX2018004737A (es) | 2015-10-23 | 2018-07-06 | Nestec Sa | Arenas higienicas de baja densidad para mascotas y metodos para elaborar tales arenas higienicas para mascotas. |
| RU2654062C2 (ru) * | 2016-07-14 | 2018-05-16 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Производные хиназолин-4(3н)-она, ингибирующие натрий-водородный обмен |
| AU2017357589B2 (en) | 2016-11-10 | 2023-05-11 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3472859A (en) * | 1966-11-01 | 1969-10-14 | Sterling Drug Inc | 1-alkyl-1,4-dihydro-4-oxo-3 quinoline-carboxylic acids and esters |
| JPS4826772A (enExample) | 1971-08-11 | 1973-04-09 | ||
| DE3501247A1 (de) | 1985-01-16 | 1986-07-17 | Bayer Ag, 5090 Leverkusen | Aminoacrylsaeure-derivate |
| US5563138A (en) * | 1987-04-16 | 1996-10-08 | Otsuka Pharmaceutical Company, Limited | Benzoheterocyclic compounds |
| EP0319906A3 (en) * | 1987-12-11 | 1990-05-02 | Dainippon Pharmaceutical Co., Ltd. | Novel quinoline derivatives, processes for preparation thereof and antibacterial agent containing them |
| US4920120A (en) * | 1988-01-25 | 1990-04-24 | Warner-Lambert Company | Antibacterial agents |
| DE3934082A1 (de) * | 1989-10-12 | 1991-04-18 | Bayer Ag | Chinoloncarbonsaeurederivate, verfahren zu ihrer herstellung sowie ihre verwendung als antivirale mittel |
| DE4015299A1 (de) * | 1990-05-12 | 1991-11-14 | Bayer Ag | Verfahren zur herstellung von 3-amino-2-(het)-aroyl-acrylsaeurederivaten |
| IL100555A (en) | 1991-02-07 | 2000-08-31 | Hoechst Marion Roussel Inc | N-substituted quinoline derivatives their preparation their use for the preparation of medicaments and the pharmaceutical compositions containing them |
| JP2993316B2 (ja) | 1992-05-27 | 1999-12-20 | 宇部興産株式会社 | アリール基又は複素芳香環基置換アミノキノロン誘導体及びエイズ治療剤 |
| NO304832B1 (no) | 1992-05-27 | 1999-02-22 | Ube Industries | Aminokinolonderivater samt middel mot HIV |
| JPH06199635A (ja) | 1992-12-28 | 1994-07-19 | Kanebo Ltd | 化粧料 |
| JPH06199835A (ja) | 1993-01-08 | 1994-07-19 | Hokuriku Seiyaku Co Ltd | ８−ジフルオロメトキシキノリン−３−カルボン酸誘導体 |
| JPH06271568A (ja) | 1993-03-22 | 1994-09-27 | Hokuriku Seiyaku Co Ltd | ７−フェニルピペラジニルキノリン−３−カルボン酸誘導体 |
| CN1147248A (zh) | 1994-04-28 | 1997-04-09 | 山之内制药株式会社 | N-(3-吡咯烷基)苯甲酰胺衍生物 |
| AU683569B2 (en) * | 1994-07-18 | 1997-11-13 | Sankyo Company Limited | Trifluoromethylquinolinecarboxylic acid derivative |
| JP2930539B2 (ja) | 1994-07-18 | 1999-08-03 | 三共株式会社 | トリフルオロメチルキノリンカルボン酸誘導体 |
| JPH08183776A (ja) | 1994-12-28 | 1996-07-16 | Hideaki Yamaguchi | 金属の表面保護剤ならびにそれを用いた製造方法 |
| US6303611B1 (en) * | 1996-03-08 | 2001-10-16 | Adolor Corporation | Kappa agonist compounds and pharmaceutical formulations thereof |
| PT892801E (pt) * | 1996-04-12 | 2002-06-28 | Us Gov Health & Human Serv | Compostos derivados de acridona uteis como agentes antineoplasicos e antiretrovirais |
| US6287550B1 (en) * | 1996-12-17 | 2001-09-11 | The Procter & Gamble Company | Animal care system and litter with reduced malodor impression |
| US5989451A (en) | 1997-02-07 | 1999-11-23 | Queen's University At Kingston | Compounds and methods for doping liquid crystal hosts |
| FR2761687B1 (fr) | 1997-04-08 | 2000-09-15 | Centre Nat Rech Scient | Derives de quinoleines, possedant notamment des proprietes antivirales, leurs preparations et leurs applications biologiques |
| JP3776203B2 (ja) | 1997-05-13 | 2006-05-17 | 第一製薬株式会社 | Ｉｃａｍ−１産生阻害剤 |
| KR20010013377A (ko) * | 1997-06-04 | 2001-02-26 | 데이비드 엠 모이어 | 마일드한 잔류성 항균 조성물 |
| TW527355B (en) | 1997-07-02 | 2003-04-11 | Bristol Myers Squibb Co | Inhibitors of farnesyl protein transferase |
| JPH1184556A (ja) | 1997-09-08 | 1999-03-26 | Konica Corp | ハロゲン化銀乳剤、該乳剤を用いる感光材料の処理方法及び撮影方法 |
| GB9721964D0 (en) | 1997-10-16 | 1997-12-17 | Pfizer Ltd | Isoquinolines |
| GB9807903D0 (en) | 1998-04-14 | 1998-06-10 | Smithkline Beecham Plc | Novel compounds |
| US6399629B1 (en) * | 1998-06-01 | 2002-06-04 | Microcide Pharmaceuticals, Inc. | Efflux pump inhibitors |
| US6248739B1 (en) | 1999-01-08 | 2001-06-19 | Pharmacia & Upjohn Company | Quinolinecarboxamides as antiviral agents |
| US6248736B1 (en) | 1999-01-08 | 2001-06-19 | Pharmacia & Upjohn Company | 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents |
| FR2795726A1 (fr) | 1999-06-30 | 2001-01-05 | Aventis Cropscience Sa | Nouveaux pyrazoles fongicides |
| DE19950898A1 (de) * | 1999-10-22 | 2001-04-26 | Aventis Pharma Gmbh | Heterocyclisch substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| PE20011349A1 (es) | 2000-06-16 | 2002-01-19 | Upjohn Co | 1-aril-4-oxo-1,4-dihidro-3-quinolincarboxamidas como agentes antivirales |
| US6559145B2 (en) | 2000-07-12 | 2003-05-06 | Pharmacia & Upjohn Company | Heterocycle carboxamides as antiviral agents |
| US6730682B2 (en) | 2000-07-12 | 2004-05-04 | Pharmacia & Upjohn Company | Heterocycle carboxamides as antiviral agents |
| US20050010048A1 (en) | 2000-10-12 | 2005-01-13 | Linghang Zhuang | Aza-and polyaza-naphthalenly ketones useful as hiv integrase inhibitors |
| ATE345129T1 (de) | 2000-10-12 | 2006-12-15 | Merck & Co Inc | Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer |
| CN1232508C (zh) * | 2000-12-14 | 2005-12-21 | 宝洁公司 | 制取喹诺酮和二氮杂萘的环化方法步骤 |
| WO2002076939A2 (en) | 2001-02-05 | 2002-10-03 | Exegenics Inc. | Cysteine protease inhibitors |
| JP3616628B2 (ja) | 2001-03-01 | 2005-02-02 | 塩野義製薬株式会社 | Ｈｉｖインテグラーゼ阻害活性を有する含窒素芳香族複素環化合物 |
| JP4518302B2 (ja) | 2001-03-19 | 2010-08-04 | 日本化薬株式会社 | 水溶性ジスアゾ化合物、水性ブラックインク組成物および着色体 |
| JP2002293745A (ja) | 2001-03-29 | 2002-10-09 | St Marianna Univ School Of Medicine | 慢性関節リウマチ治療剤 |
| JP3980842B2 (ja) | 2001-05-11 | 2007-09-26 | バブコック日立株式会社 | アンモニア含有排水の浄化装置および浄化方法 |
| JP2003065807A (ja) | 2001-08-29 | 2003-03-05 | Mitsubishi Electric Corp | プロセスデータのトレンド表示方法および装置 |
| JP3913037B2 (ja) | 2001-10-30 | 2007-05-09 | 三菱電機株式会社 | 赤外線検出器 |
| TW200300349A (en) | 2001-11-19 | 2003-06-01 | Sankyo Co | A 4-oxoqinoline derivative |
| DE60329318D1 (de) * | 2002-11-20 | 2009-10-29 | Japan Tobacco Inc | 4-oxochinolinverbindungen und deren verwendung als hiv-integrase-inhibitoren |
| JP2004253231A (ja) | 2003-02-20 | 2004-09-09 | Pioneer Electronic Corp | プラズマディスプレイパネル |
| WO2005113509A1 (en) * | 2004-05-20 | 2005-12-01 | Japan Tobacco Inc. | Novel 4-oxoquinoline compound and use thereof as hiv integrase inhibitor |
| MY134672A (en) * | 2004-05-20 | 2007-12-31 | Japan Tobacco Inc | Stable crystal of 4-oxoquinoline compound |
| US8633219B2 (en) * | 2004-05-21 | 2014-01-21 | Japan Tobacco Inc. | Combination therapy |
| KR101023635B1 (ko) | 2006-03-06 | 2011-03-22 | 니뽄 다바코 산교 가부시키가이샤 | 4-옥소퀴놀린 화합물 제조 방법 |
| CN101437801B (zh) | 2006-03-06 | 2013-02-06 | 日本烟草产业株式会社 | 制备4-氧代喹啉化合物的方法 |
| TW200811153A (en) * | 2006-06-23 | 2008-03-01 | Japan Tobacco Inc | 6-(heterocyclyl-substituted benzyl)-4-oxoquinoline compound and use thereof as HIV integrase inhibitor |
| EP2644587A3 (en) | 2006-09-12 | 2013-10-23 | Gilead Sciences, Inc. | Process and intermediates for preparing integrase inhibitors |
| AR068403A1 (es) | 2007-09-11 | 2009-11-18 | Gilead Sciences Inc | Proceso e intermediarios para la preparacion de inhibidores de integrasa |
| EP2197847B1 (en) * | 2007-09-12 | 2012-11-07 | Concert Pharmaceuticals Inc. | Deuterated 4 -oxoquinoline derivative for the treatment of hiv infection |
| WO2009089263A2 (en) | 2008-01-07 | 2009-07-16 | Ardea Biosciences Inc. | Novel compositions and methods of use |
| SI23420A (sl) | 2010-07-22 | 2012-01-31 | Institut "Jožef Stefan" | Kostni vsadki z večslojno prevleko in postopek njihove priprave |
| US11347056B2 (en) | 2018-08-22 | 2022-05-31 | Microsoft Technology Licensing, Llc | Foveated color correction to improve color uniformity of head-mounted displays |
| JP7397852B2 (ja) | 2018-08-23 | 2023-12-13 | エルジー イノテック カンパニー リミテッド | センシング装置 |
| WO2020040561A1 (ko) | 2018-08-24 | 2020-02-27 | 한온시스템 주식회사 | 차량용 공조장치 |
-
2003
- 2003-11-20 DE DE60329318T patent/DE60329318D1/de not_active Expired - Lifetime
- 2003-11-20 IL IL16254803A patent/IL162548A0/xx unknown
- 2003-11-20 PE PE2003001176A patent/PE20040840A1/es active IP Right Grant
- 2003-11-20 SK SK266-2004A patent/SK2662004A3/sk not_active Application Discontinuation
- 2003-11-20 EP EP09169859A patent/EP2161258A3/en not_active Withdrawn
- 2003-11-20 EP EP18166352.7A patent/EP3406596A1/en not_active Withdrawn
- 2003-11-20 NZ NZ533641A patent/NZ533641A/en not_active IP Right Cessation
- 2003-11-20 CA CA2470365A patent/CA2470365C/en not_active Expired - Lifetime
- 2003-11-20 EP EP22158433.7A patent/EP4059923A1/en active Pending
- 2003-11-20 WO PCT/JP2003/014773 patent/WO2004046115A1/ja not_active Ceased
- 2003-11-20 EP EP10011216A patent/EP2272516A3/en not_active Withdrawn
- 2003-11-20 BR BRPI0306214-7A patent/BRPI0306214B1/pt not_active IP Right Cessation
- 2003-11-20 MY MYPI20034478A patent/MY136173A/en unknown
- 2003-11-20 AR ARP030104286A patent/AR042095A1/es active IP Right Grant
- 2003-11-20 US US10/492,833 patent/US7176220B2/en active Active
- 2003-11-20 SI SI200331707T patent/SI1564210T1/sl unknown
- 2003-11-20 TW TW092132527A patent/TWI248928B/zh not_active IP Right Cessation
- 2003-11-20 AU AU2003302029A patent/AU2003302029B8/en active Active
- 2003-11-20 DK DK03811532.5T patent/DK1564210T5/da active
- 2003-11-20 EP EP03811532A patent/EP1564210B9/en not_active Expired - Lifetime
- 2003-11-20 PT PT03811532T patent/PT1564210E/pt unknown
- 2003-11-20 TR TR2004/01663T patent/TR200401663T1/xx unknown
- 2003-11-20 AT AT03811532T patent/ATE443048T1/de active
- 2003-11-20 KR KR1020047010082A patent/KR100665919B1/ko not_active Expired - Lifetime
- 2003-11-20 ES ES03811532T patent/ES2329240T3/es not_active Expired - Lifetime
- 2003-11-20 CZ CZ2004764A patent/CZ2004764A3/cs unknown
-
2004
- 2004-06-08 ZA ZA2004/04537A patent/ZA200404537B/en unknown
- 2004-06-16 IL IL162548A patent/IL162548A/en active Protection Beyond IP Right Term
- 2004-07-02 MX MXPA04006553A patent/MXPA04006553A/es active IP Right Grant
- 2004-07-14 NO NO20043004A patent/NO327098B1/no not_active IP Right Cessation
-
2006
- 2006-06-05 US US11/446,128 patent/US8232401B2/en active Active
-
2009
- 2009-12-11 CY CY20091101301T patent/CY1110690T1/el unknown
-
2012
- 2012-06-20 US US13/528,688 patent/US20130172344A1/en not_active Abandoned
- 2012-07-03 AR ARP120102410A patent/AR087046A2/es unknown
-
2013
- 2013-07-12 LT LTPA2013018C patent/LTPA2013018I1/lt unknown
- 2013-11-07 NO NO2013015C patent/NO2013015I2/no unknown
- 2013-11-07 HU HUS1300066C patent/HUS1300066I1/hu unknown
- 2013-11-11 LU LU92307C patent/LU92307I2/fr unknown
- 2013-11-12 FR FR13C0061C patent/FR13C0061I2/fr active Active
- 2013-11-14 BE BE2013C063C patent/BE2013C063I2/fr unknown
- 2013-11-18 CY CY2013043C patent/CY2013043I1/el unknown
-
2014
- 2014-06-10 US US14/301,083 patent/US20150174117A1/en not_active Abandoned
-
2019
- 2019-05-10 US US16/409,728 patent/US20200101061A1/en not_active Abandoned
-
2022
- 2022-05-13 US US17/663,391 patent/US20230190730A1/en not_active Abandoned
- 2022-07-22 NO NO2022032C patent/NO2022032I1/no unknown